Bavarian Nordic upgrades again following new batch of monkeypox contracts

The vaccine maker last adjusted its financial expectation on Friday, and followed up with newer target figures on Monday due to even more orders for its smallpox vaccine, Jynneos.

Photo: Lukas Barth/Reuters/Ritzau Scanpix

Bavarian Nordic has just upgraded its financial outlook for 2022 again, coming not long after the last time the vaccine maker saw the opportunity to do so.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs